|1.||Kou, Junping: 6 articles (01/2015 - 07/2005)|
|2.||Yu, Boyang: 6 articles (01/2015 - 07/2005)|
|3.||Liu, I-Min: 3 articles (07/2014 - 01/2014)|
|4.||Liou, Shorong-Shii: 3 articles (07/2014 - 01/2014)|
|5.||Wu, Ming-Chang: 3 articles (07/2014 - 01/2014)|
|6.||Lu, Hung-Jen: 3 articles (07/2014 - 01/2014)|
|7.||Chang, Chia Ju: 2 articles (07/2014 - 01/2014)|
|8.||Yang, Cheng: 2 articles (07/2014 - 01/2014)|
|9.||Tzeng, Thing-Fong: 2 articles (01/2014 - 01/2014)|
|10.||Su, Wei-Wei: 1 article (01/2015)|
07/01/2014 - "The protective effects of ruscogenin on nonalcoholic steatohepatitis in hamsters fed a high-fat diet were investigated. "
01/01/2014 - "The aim of the study was to investigate the protective effects of ruscogenin, a major steroid sapogenin in Ophiopogon japonicus, on experimental models of nonalcoholic steatohepatitis. "
01/01/2014 - "Ruscogenin ameliorates experimental nonalcoholic steatohepatitis via suppressing lipogenesis and inflammatory pathway."
07/01/2014 - "Ruscogenin protects against high-fat diet-induced nonalcoholic steatohepatitis in hamsters."
01/01/2014 - "Ruscogenin alleviated dyslipidemia, liver steatosis, and necroinflammation and reversed plasma markers of metabolic syndrome in HFD-fed hamsters. "
|2.||Diabetic Nephropathies (Diabetic Nephropathy)
01/01/2014 - "Our data demonstrated that ruscogenin suppressed the inflammation and ameliorated the structural and functional abnormalities of the diabetic kidney in rats might be associated with inhibition of NF-κB mediated inflammatory genes expression."
01/01/2015 - "This study aimed to explore the effect of DT-13 (25(R,S)-ruscogenin- 1-O- [β-d-glucopyranosyl- (1→2)][β-d-xylopyranosyl-(1→3)]-β -d- fucopyranoside) on tumor necrosis factor (TNF)-α-induced vascular inflammation and the potential molecular mechanisms. "
07/01/2005 - "These results demonstrate that ROJ-ext presents remarkable anti-inflammatory activity and ruscogenin and ophiopogonin D are two of its active components, which supported its traditional use in the treatment of various diseases associated with inflammation."
|4.||Acute Lung Injury
01/01/2012 - "Here, we studied the inhibitory effect of ruscogenin, an anti-inflammatory and anti-thrombotic natural product, on lipopolysaccharide (LPS)-induced acute lung injury in mice basing on our previous studies. "
01/01/2012 - "These findings confirmed that ruscogenin significantly attenuate LPS-induced acute lung injury via inhibiting expressions of TF and iNOS and NF-κB p65 activation, indicating it as a potential therapeutic agent for ALI or sepsis."
01/01/2012 - "Ruscogenin inhibits lipopolysaccharide-induced acute lung injury in mice: involvement of tissue factor, inducible NO synthase and nuclear factor (NF)-κB."
08/16/1984 - "In patients with postthrombotic syndrome the medium blood stream velocity in the V. femoralis increased on the diseased side two hours after oral application of a high-dosed combination of ruscogenin, trimethyl-hesperidin-chalkon and ascorbic acid (1 X 6 capsules Phlebodril) by the mean of 24%. "
|2.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|4.||Proteins (Proteins, Gene)
|7.||Nitric Oxide Synthase (NO Synthase)
|9.||Interleukin-8 (Interleukin 8)
|10.||Interleukin-6 (Interleukin 6)